
Tirzepatide 10mg Metabolismo
-22 % de peso. GIP + GLP-1.
El doble agonista de última generación. GIP + GLP-1 reunidos — estimulación hormonal combinada para una pérdida de peso documentada del -22% en 72 semanas (SURMOUNT-1). Supera a Semaglutide en eficacia directa. La nueva referencia FDA. El futuro de la pérdida de peso dirigida.
Inicio de los protocolos de investigación: 50 unidades, es decir 2,5 mg por semana (vial preparado con 2 ml de agua).
10 mg = el contenido del vial, no la dosis.Ver la preparación
- Stock en Francia
Pedido con su agua: enviado en estuche imantado
-10 % en cada envíoPause, salte o cancele en 1 clicSin compromiso, sin gastos ocultos
Sin cargo automático: pague cada envío con tarjeta, en Bitcoin (-5 % adicional) o por transferencia desde 100 €
Tu kit completo
El vial por sí solo no puede usarse tal cual. Añada lo necesario para prepararlo:
Se compran juntos a menudo
Uso exclusivo en investigación (RUO) · Prohibido para uso humano o veterinario.
Lo esencial
Tirzepatide 10mg is the entry format giving access to the GLP-1/GIP dual agonism documented by SURPASS and SURMOUNT without heavy volumetric commitment. This vial is sized for titration phases and short exploratory research cycles: starter vial, 4 weeks on the progressive protocol (start at 2.5 mg per week). For researchers discovering the molecule or calibrating a first protocol, the 10mg format validates individual tolerance, adjusts titration to subject physiology, and measures early metabolic markers (fasting glucose, HbA1c, body mass, waist circumference, lipids) before committing to a long cycle. Its compact format also minimizes financial risk if discontinuation is decided early in the cycle.
En detalle
Range positioning10mg is the rational entry point vs 15mg (standard SURMOUNT-1 target dose), 30mg (long-cycle, 3 to 6 weeks at the maintenance level of 5 to 10 mg per week), or 60mg (mega-cycle, 6 to 12 weeks at the same level). Reconstituted at 2 mL bacteriostatic water, it delivers 5 mg/mL: 50 units on a U100 syringe = 2.5 mg. At target dose 10mg/week (SURMOUNT-1 plateau week 13-16), one vial covers exactly 1 full week; at 5mg/week (plateau week 5-8) it covers 2 weeks; at 2.5mg initial dose, 4 weeks. The format thus suits both calibration and short-segment validation equally.
Protocolo y preparación
| Agua añadida | Concentración | Marca de lectura |
|---|---|---|
| 1 ml | 10 mg/ml | 10 UI = 1 mg |
| 2 ml | 5 mg/ml | 40 UI = 2 mg |
El volumen de agua no cambia el producto, solo su concentración. Introduzca el agua despacio por la pared del vial, nunca directamente sobre el liofilizado, y luego gírelo suavemente sin agitar. Las marcas se dan sobre una jeringa de 1 ml graduada en 100 unidades.
Asepsia
Desinfecte las superficies y los tapones (alcohol al 70%).
Disolvente
Extraiga el volumen necesario de agua bacteriostática.
Introducción
Inyecte suavemente contra la pared del vial (evite el chorro directo sobre el polvo).
Solubilización
Haga rodar el vial suavemente. No lo agite con fuerza (riesgo de degradación).
Conservación de la solución Una vez reconstituido: 2-8°C (nevera).
Advertencia Herramienta teórica para manipulación química. No constituye un consejo médico.
Abrir la calculadora de dilución- La cantidad de polvo parece mínima. Un liofilizado ocupa unos pocos milímetros en el fondo del vial, a veces solo una película translúcida. El peso indicado está ahí.
- El polvo está compacto, pegado a la pared o al tapón. El transporte desplaza la torta liofilizada. No cambia nada en la reconstitución.
- El vial no lleva etiqueta individual. Es nuestro embalaje estándar, no un vial de menor calidad.
- Tras la reconstitución aparecen depósitos o filamentos. Es habitual, sobre todo con moléculas pequeñas. Deje que se asiente y haga rodar el vial entre las palmas, nunca lo agite.
- El paquete es neutro. Nada en el exterior indica el contenido ni el nombre de la marca.
Lo que no es normal: un vial agrietado, una cápsula sin engastar o un tapón que se mueve, polvo que se ha licuado o cambiado de color. En esos casos concretos, escríbanos con una foto y recuperamos el vial.
The SURMOUNT-1 reference protocol (Jastreboff 2022 NEJM) is the usual matrix. Phase 1 titration (weeks 1-20): 2.5mg weekly W1-4, 5mg W5-8, 7.5mg W9-12, 10mg W13-16, 12.5mg W17-20, 15mg W21+. With a 10mg vial, researchers often begin with the initial phase: 2.5mg/week for 4 weeks (one vial covers the whole period), then transition to 15mg or repeat a 10mg to reach the 5mg plateau.
Option AInitial titration protocol (4 weeks, 2.5mg/week): reconstitute 10mg with 2 mL bacteriostatic water (concentration 5 mg/mL). Draw 0.5 mL (50 units on U100 syringe) delivers 2.5mg. One vial = 4 doses of 2.5mg = 4 weeks of initial titration. Ideal for validating individual tolerance before long commitment.
Option B10mg plateau protocol (1 week): reconstitute 10mg with 2 mL (concentration 5 mg/mL). Drawing two full U100 syringes (2 × 100 units = 2 mL) delivers 10mg in a single session. One vial = 1 week at target dose 10mg (SURMOUNT-1 W13-16 plateau). Option for researchers in progressive up-titration wishing to validate this specific plateau.
Option CIntermediate 5mg/week protocol (2 weeks): reconstitute 10mg with 2 mL (5 mg/mL). Draw 1 mL (100 units) delivers 5mg. One vial = 2 weeks at SURMOUNT-1 W5-8 plateau.
Injection siteRotate across 4 abdominal subcutaneous zones (right upper, right lower, left upper, left lower quadrants), minimum 2.5 cm from navel. Alternate weekly to prevent lipohypertrophy. Anterolateral thigh and flank are valid alternatives. Bevel up, angle 45-90 degrees depending on skinfold thickness. Aspirate if unsure, inject slowly (5-10 seconds), hold 10 seconds before withdrawal.
Minimum monitoringWeekly weight at fixed time, waist every 15 days, fasting glucose every 4 weeks (or continuous via CGM for advanced protocols), HbA1c at W0, W12, W24. Daily adverse event journal for the first 4 weeks (nausea, satiety, fatigue, bowel movements).
Datos técnicos
- Reconstitución
- 2 ml d'eau → 5 mg/ml. 50 UI = 2,5 mg.
- Secuencia peptídica
- YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS-NH2 (X = Aib ; lysine acylée)
- Fórmula molecular
- C225H348N48O68
- Peso molecular
- 4813.45 g/mol
- Número CAS
- 2023788-19-2
- Forma física
- Poudre lyophilisée
- Solubilidad recomendada
- Eau bactériostatique, NaCl 0,9%
- Condiciones de conservación
- Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
- Uso
- Reactivo de investigación, solo in vitro (RUO)
Conservación y manipulación
Lyophilized tirzepatide stability is robust as long as the cold chain is maintained. The product stores up to 24 months at 2-8 °C, protected from light in its original packaging. Freezing below -20 °C, though sometimes practiced for extended stockpiles, adds no documented benefit for the intact peptide and introduces freeze-thaw cycle risk if storage is unstable. After reconstitution with bacteriostatic water, the solution stores for 21 to 28 days at 2-8 °C, still protected from light. The 0.9% benzyl alcohol in bacteriostatic water preserves microbiological sterility but does not halt chemical peptide degradation, which continues slowly even under refrigeration. Dominant degradation pathways for tirzepatide are methionine oxidation (Met27), asparagine deamidation and glutamine deamidation, along with oligomer formation via hydrophobic interactions involving the C20 acyl chain. A 5-10% activity loss after 28 days is expected, usable in research but to be factored into dose-response calculations over extended cycles. In the laboratory, a few operational rules are essential. (1) Minimize fridge entries/exits: every thermal shock accelerates degradation. Remove the vial just before sampling, return to cold storage within 10 minutes. (2) Never shake vigorously: the C20 chain readily generates oligomers if the solution is subjected to shear (shaker, vortex). Tilt gently or let dissolve spontaneously. (3) Light protection: amber glass vials from original packaging are effective; if transferring to clear tubes, wrap in aluminum. (4) Document the cold chain with a temperature logger on the dedicated peptide fridge, with SMS alert on threshold breach. In cohort production, a strict dating protocol is required. Label each reconstituted vial with date, time, final concentration, initial lot, and operator initials. Plan samplings to exhaust the vial before day 28 as priority, minimizing reject percentage. For long cycles (> 8 weeks), prefer volumetric formats adapted to cycle duration (30mg or 60mg) rather than chaining 10 or 15mg reconstitutions, which multiply manipulations and contamination risks. The economical format matched to cycle length is the best anti-degradation and anti-waste strategy.
Mecanismo de acción
Tirzepatide is the first marketed dual incretin-mimetic agonist. Its 39-residue sequence derives from native human GIP (Glucose-dependent Insulinotropic Polypeptide), with engineered modifications that confer simultaneous high affinity at two G-protein-coupled receptors: GLP-1R and GIPR. Coskun and colleagues (Mol Metab 2018) described the rational design: Aib substitutions at positions 2 and 20 blocking DPP-4 cleavage, and a C20 diacid fatty-acyl chain attached to Lys20 via a gamma-glutamate linker that anchors the molecule to serum albumin and extends the half-life to roughly 117 hours in humans.
Tirzepatide biology is not simply the sum of GLP-1 plus GIP activity. The GIPR-biased sequence (picomolar-range EC50 at GIPR, sub-nanomolar at GLP-1R) creates a qualitatively distinct signaling signature. Willard et al. (JCI Insight 2020) demonstrated that tirzepatide recruits beta-arrestin less strongly at GLP-1R than native GLP-1, producing a bias toward Galpha-s / cAMP signaling that may limit receptor desensitization. At GIPR, conversely, tirzepatide behaves as a full agonist. This signaling architecture partly explains the clinical metabolic superiority observed over single GLP-1 agonists.
The GIP arm adds mechanisms absent from single agonists. In adipose tissue, GIPR activation stimulates postprandial lipogenesis and triglyceride clearance while improving insulin sensitivity in subcutaneous adipocytes. In the central nervous system, GIPR neurons in the arcuate and paraventricular nuclei modulate appetite additively with GLP-1R neurons. Preclinical models (GIPR-KO mice, obese rats) suggest that GIP/GLP-1 co-activation increases thermogenic energy expenditure through brown adipose tissue, contributing to weight loss beyond caloric restriction.
At the pancreatic level, the incretin effect is potentiated synergistically: tirzepatide administration in type 2 diabetic subjects triggers glucose-dependent insulin secretion exceeding a reference GLP-1 mono-agonist, without clinical hypoglycemia (Heise 2022 Diabetes Care). GLP-1 glucagonostatic action stabilizes fasting glycemia. Gastric emptying is also slowed, contributing to satiety but demanding attention to drug interactions and gastrointestinal discomfort during rapid titrations.
Pharmacokinetics justify the weekly regimen. Cmax is reached 24-72 hours post-injection depending on dose, terminal half-life 117 hours, steady-state achieved within 4 weeks on a fixed weekly dose. Clearance is essentially proteolytic (no significant CYP450 biotransformation), limiting pharmacokinetic interactions. In research contexts this pharmacokinetic window is precious: weekly administration produces near-stationary plasma concentrations, facilitating protocol standardization and reproducibility of cohort measurements.
Estudios y referencias
The tirzepatide clinical program spans two armsType 2 diabetes (SURPASS) and obesity without diabetes (SURMOUNT). Phase III trial density is substantial and positions the molecule as one of the best-documented incretin agents to date.
SURPASS-1 (Rosenstock 2021, Lancet) compared tirzepatide 5/10/15mg weekly to placebo in 478 drug-naive T2D patients over 40 weeks. HbA1c reductions: -1.87% (5mg), -1.89% (10mg), -2.07% (15mg) vs -0.04% placebo. Weight loss: -7.0 to -9.5 kg dose-dependent. SURPASS-2 (Frias 2021, NEJM) was the pivotal head-to-head trial against semaglutide 1mg in 1879 patients over 40 weeks. Tirzepatide 15mg produced HbA1c reduction -2.30% vs -1.86% for semaglutide 1mg, and weight loss -11.2 kg vs -5.7 kg. This trial established the metabolic superiority of the dual agonist over the reference GLP-1 mono-agonist.
SURPASS-3 (Ludvik 2021) added tirzepatide to metformin vs insulin degludec in 1437 patients over 52 weeks: marked superiority in HbA1c reduction and weight loss, with fewer hypoglycemia events. SURPASS-4 (Del Prato 2021, Lancet) extended evaluation to high cardiovascular risk patients over 104 weeks: durable HbA1c and weight reductions, reassuring cardiovascular profile. SURPASS-5 (Dahl 2022, JAMA) tested addition to insulin glargine: HbA1c -2.40% (15mg), weight -10.9 kg, substantial metabolic improvement.
The SURMOUNT program targets obesity without diabetes. SURMOUNT-1 (Jastreboff 2022, NEJM) enrolled 2539 adults BMI >= 30 (or >= 27 with comorbidities) over 72 weeks. Mean weight loss: -15.0% (5mg), -19.5% (10mg), -20.9% (15mg) vs -3.1% placebo. 50.1% of 15mg patients reached >= 20% weight loss, 36.2% reached >= 25%.
SURMOUNT-2 (Garvey 2023, Lancet) validated the effect in diabetic obese patients (-13.4% @15mg over 72 weeks). SURMOUNT-3 (Wadden 2023, Nat Med) showed that after a 12-week intensive diet lead-in, adding tirzepatide 10/15mg generated -18.4% additional loss over 72 weeks vs +2.5% placebo. SURMOUNT-4 (Aronne 2024, JAMA) tested withdrawal: after 36 weeks of maximal tirzepatide followed by 52 weeks of maintenance or discontinuation, the discontinuation group regained 14.0% of body weight while the maintenance group lost an additional 5.5%. Practical conclusion: ongoing therapy is required to preserve benefit, consistent with obesity as a chronic disease.
Ancillary data support systemic benefits. SURPASS-CVOT (ongoing cardiovascular trial, results expected 2025-2026) will compare tirzepatide to dulaglutide in 13299 high-CV-risk T2D patients. SYNERGY-NASH (Loomba 2024, NEJM) documented MASH resolution without fibrosis worsening in 51.8% of tirzepatide 10mg patients vs 9.8% placebo. Effects on sleep apnea (SURMOUNT-OSA, Malhotra 2024 NEJM) show a 55% reduction in apnea-hypopnea index at 52 weeks. These data sketch a cross-cutting therapeutic profile few agents share.
In research these references structure protocol designTitration regimens used in trials (2.5mg weeks 1-4 then +2.5mg every 4 weeks to target dose) serve as a methodological framework for exploratory cohorts, and stopping criteria (severe gastrointestinal events, pancreatitis, hypersensitivity reactions) inform exclusion criteria for observational work.
- 1
- 2
- 3
Péptidos similares
Versus semaglutide (GLP-1 mono-agonist): head-to-head superiority demonstrated in SURPASS-2 (Frias 2021 NEJM). Tirzepatide 15mg beats semaglutide 1mg by +0.44% additional HbA1c and +5.5 kg additional weight loss. The GIP arm contributes measurably to visceral fat and energy expenditure. Limit: slower titration (5 steps to 15mg) and stricter gastrointestinal tolerance in the first weeks.
Versus retatrutide (GLP-1/GIP/GCGR triple agonist): retatrutide adds a glucagon arm that stimulates hepatic thermogenesis and lipolysis. Phase II data (Jastreboff 2023 NEJM) show -24.2% at 12mg/48w vs -20.9% for tirzepatide 15mg/72w, a notable gap. But retatrutide is newer, with fewer long-term data, and the GCGR component demands heightened vigilance on hepatic function. Tirzepatide retains the advantage of clinical maturity (>400 publications) and better-mapped tolerance profile.
Versus liraglutide 3mg (Saxenda): liraglutide is a daily GLP-1 mono-agonist with -8% weight loss over 56 weeks (Pi-Sunyer 2015 NEJM SCALE). Tirzepatide 15mg weekly produces -20.9% over 72 weeks, an absolute gain of >12 percentage points. The posology advantage (1 weekly injection vs 1 daily) and 2.5x superior efficacy make liraglutide obsolete as first-line weight loss agent.
Versus dulaglutide (Trulicity): dulaglutide is a weekly GLP-1 agonist with modest weight loss (-3 to -4 kg at 1.5mg). Tirzepatide is 4-5x superior on weight outcomes. Direct comparison awaits SURPASS-CVOT (2025-2026 results) for cardiovascular events.
Versus basal insulin: SURPASS-3 and SURPASS-5 show that adding tirzepatide to antidiabetic therapy outperforms titrating basal insulin, without weight gain or hypoglycemia. Insulin remains essential in type 1 diabetes and acute type 2 decompensation, but as a type 2 intensification agent, tirzepatide is superior.
Versus bupropion-naltrexone (Contrave/Mysimba), orlistat (Xenical), phentermine-topiramate (Qsymia): these agents produce 3-10% weight loss and are eclipsed by tirzepatide (2-7x more effective by comparison). Their residual advantages: oral form, much lower cost, no injection requirement.
Research positioning: tirzepatide is today's peptide of choice for exploratory protocols combining maximal metabolic efficacy and documented tolerance profile. Its data maturity surpasses retatrutide's and rivals semaglutide's, while offering a higher intensity of effect than the mono-agonist.
Preguntas frecuentes
Why is tirzepatide called a "dual agonist" and what does it change in practice?
What volume of bacteriostatic water should be used to reconstitute a tirzepatide vial?
How long can reconstituted tirzepatide be stored, and what signs indicate degradation?
Why must tirzepatide be titrated progressively?
What are key drug interactions and contraindications for tirzepatide?
Can tirzepatide be combined with other research peptides (BPC-157, TB-500, CJC-1295)?
Which format should I choose for a long cohort protocol (16+ weeks)?
Why should tirzepatide never be mixed in the same syringe as insulin or another peptide?
La guía completaTirzepatida: guía completa del co-agonista GLP-1R / GIPR en investigación preclínicaDosier técnico sobre la tirzepatida para uso en investigación: estructura híbrida GIP-GLP-1, activación dual GLP-1R/GIPR, farmacocinética, sinergia incretina, modelos DIO y ZDF, control analítico. Uso estrictamente RUO.Leer la guía Lee también:Tirzepatide: la página dedicadaCagrilintida (AM-833): guía completa del análogo de amilina de acción prolongada en investigación metabólicaRetatrutida (LY3437943): guía completa del triple agonista
